SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
SNAP
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
124 13 0 SNAP
Emcee:  scaram(o)uche Type:  Unmoderated
I'm surprised that there's not been a Synaptic thread. If I had to sell everything in my portfolio, SNAP might be the last holding to go. It's for the patient investor, however.

This is another company that John De Castro pointed out for me. SNAP, to me, is one of those companies where, as one component of a basket of similar companies, you can close your eyes for five years and wake up rich. There should be another partnership (to complement those with Ciba-Geigy/Novartis, Lilly and Merck) announced soon. Here's an interesting abstract.......

Medline ID:
96177284
Citation:
Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL,
Foster D,
Lasser G, Prunkard DE, Porte D Jr, Woods SC, Seeley
RJ,
Weigle DS, Specificity of leptin action on elevated
blood
glucose levels and hypothalamic neuropeptide Y gene
expression in ob/ob mice., Diabetes 45: 4, 531-5,
Apr, 1996.

Abstract
Correction of the obese state induced by genetic leptin deficiency
reduces elevated levels
of both blood glucose and hypothalamic neuropeptide Y (NPY) mRNA in
ob/ob mice. To
determine whether these responses are due to a specific action of
leptin or to the reversal
of the obese state, we investigated the specificity of the effect of
systemic leptin
administration to ob/ob mice (n = 8) on levels of plasma glucose and
insulin and on
hypothalamic expression of NPY mRNA. Saline-treated controls were
either fed ad
libitum (n = 8) or pair-fed to the intake of the leptin-treated group
(n = 8) to control for
changes of food intake induced by leptin. The specificity of the
effect of leptin was
further assessed by 1) measuring NPY gene expression in db/db mice (n
= 6) that are
resistant to leptin, 2) measuring NPY gene expression in brain areas
outside the
hypothalamus, and 3) measuring the effect of leptin administration on
hypothalamic
expression of corticotropin-releasing hormone (CRH) mRNA. Five daily
intraperitoneal
injections of recombinant mouse leptin (150 micrograms) in ob/ob mice
lowered food
intake by 56% (P < 0.05), body weight by 4.1% (P < 0.05), and levels
of NPY mRNA in
the hypothalamic arcuate nucleus by 42.3% (P < 0.05) as compared with
saline-treated
controls. Pair-feeding of ob/ob mice to the intake of leptin-treated
animals produced
equivalent weight loss, but did not alter expression of NPY mRNA in
the arcuate nucleus.
Leptin administration was also without effect on food intake, body
weight, or NPY
mRNA levels in the arcuate nucleus of db/db mice. In ob/ob mice,
leptin did not alter
NPY mRNA levels in cerebral cortex or hippocampus or the expression
of CRH mRNA
in the hypothalamic paraventricular nucleus (PVN). Leptin
administration to ob/ob mice
also markedly reduced serum glucose (8.3 +/- 1.2 vs. 24.5 +/- 3.8
mmol/l; P < 0.01) and
insulin levels (7,263 +/- 1,309 vs. 3,150 +/- 780 pmol/l), but was
ineffective in db/db
mice. Pair-fed mice experienced reductions of glucose and insulin
levels that were < 60%
of the reduction induced by leptin. The results suggest that in ob/ob
mice, systemic
administration of leptin inhibits NPY gene overexpression through a
specific action in the
arcuate nucleus and exerts a hypoglycemic action that is partly
independent of its
weight-reducing effects. Furthermore, both effects occur before
reversal of the obesity
syndrome. Defective leptin signaling due to either leptin deficiency
(in ob/ob mice) or
leptin resistance (in db/db mice) therefore leads directly to
hyperglycemia and the
overexpression of hypothalamic NPY that is implicated in the
pathogenesis of the obesity
syndrome.

************************
Disclaimer: I own shares of SNAP, and I have a vested interest in their appreciation. I am not qualified to make recommendations. Do your own homework.

Cheers! Rick
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
124Kathleen Mullinix is CEO of WellGen (as of September 2006) wellgen.comMike McFarland-3/24/2007
123CNS Drugs. 2006;20(8):633-54. Links Galanin receptor antagonists : a potential scaram(o)uche-8/11/2006
122Errol de Souza, Ph.D., has been appointed President and CEO synapticcorp.comMike McFarland-9/10/2002
121Synaptic Pharmaceutical Enters Into an Agreement with Ranbaxy for a License to Inigel bates-7/11/2002
120Synaptic Pharmaceutical Licenses Compounds To Procter & Gamble PARAMUS, N.Jnigel bates-7/10/2002
119Synaptic Pharmaceutical Initiates Phase-I Clinical Trial For Antidepressant SNECnigel bates-2/5/2002
118PARAMUS, N.J.--(BUSINESS WIRE)--Feb. 4, 2002--Synaptic Pharmaceutical Corporationigel bates-2/4/2002
117Never noticed this (& had almost forgotten I owned a few <g>) - PARAMnigel bates-1/10/2002
116CAT, INCY, SNAP: it's clearly change of management week - Synaptic Pharmacenigel bates-11/27/2001
115PHILADELPHIA, Nov. 16 /PRNewswire/ -- The leading industry and academic researchnigel bates-11/16/2001
114Featured in The Scientist's 'hot paper' of the month - (http://www.nigel bates-11/6/2001
113Synaptic Pharmaceutical Closes $41.0 Million Private Financing Led By Warburg Pinigel bates-9/27/2001
112PARAMUS, N.J., Aug. 6 /PRNewswire/ -- Synaptic Pharmaceutical Corporation (Nasdanigel bates-8/6/2001
111Would it not be sensible for them to sell themselves to someone like NBIX ? My gnigel bates-7/19/2001
110The Looney Brothers, together with some consulting group that had it's head scaram(o)uche-7/18/2001
109Synaptic Pharmaceutical Scientists Use 'Biogenomics' to Find Elusive Recnigel bates-7/18/2001
108Whatever the reason, looks like the shares will be fixed, er, affixed to a new Mike McFarland-7/17/2001
107Mike, In 5 days of "decline" the total trading volume was 29500 shareshmpa-7/13/2001
106Just chit chat here Miljenko, no bioscience, so disregard if shareprice banter aMike McFarland-7/13/2001
105I am sure that almost all pharma are looking for antagonist of the new MCH2 receMiljenko Zuanic-6/21/2001
104Just to add a couple of notes to the MCH receptor arena. SNAP was issued two USBiotech Jim-6/21/2001
103Proc. Natl. Acad. Sci. USA, Vol. 98, Issue 13, 7564-7569, June 19, 2001 NeurobioMiljenko Zuanic-6/19/2001
10212/11/2000 Synaptic Pharmaceutical Awarded Patent For The Alpha Adrenergic 1B anMike McFarland-2/2/2001
101Shareholder grumble-- (from Yahoo) 12-Oct-00 MULLINIX, KATHLEEN P Chairman of tMike McFarland-11/18/2000
100Synaptic Pharmaceutical Announces Discovery of New Class of Receptors synapticcoMike McFarland-11/8/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):